Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
Jin‐Yu Sun, Dengke Zhang, Songquan Wu, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 183

Showing 1-25 of 183 citing articles:

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 286
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1213-1227
Open Access | Times Cited: 263
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Wei Huang, Tian-Qi Chen, Ke Fang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 188
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 103
Targeting macrophages in hematological malignancies: recent advances and future directions
Wei Li, Fang Wang, Rongqun Guo, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 98
Tumor Abnormality-Oriented Nanomedicine Design
Quan Zhou, Jiajia Xiang, Nasha Qiu, et al.
Chemical Reviews (2023) Vol. 123, Iss. 18, pp. 10920-10989
Closed Access | Times Cited: 81
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, et al.
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1248-1265
Open Access | Times Cited: 75
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 71
Targeting Cbl-b in cancer immunotherapy
Ryan C. Augustin, Riyue Bao, Jason J. Luke
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e006007-e006007
Open Access | Times Cited: 50
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 43
Ferroptosis: CD8+T cells’ blade to destroy tumor cells or poison for self-destruction
Yuan Liang, Yixin Zhao, Zhili Qi, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Wenjing Qian, Mingfang Zhao, Ruoyu Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 80
PD−L1 immunostaining: what pathologists need to know
Mohammed Akhtar, Sameera Rashid, Issam Al‐Bozom
Diagnostic Pathology (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 72
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 66
Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance
Fabrizio Fontana, Emanuela Carollo, Genevieve E. Melling, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 749-749
Open Access | Times Cited: 65
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
Eun-Sil Sung, Minkyung Ko, Ju‐young Won, et al.
Molecular Therapy (2022) Vol. 30, Iss. 8, pp. 2800-2816
Open Access | Times Cited: 59
Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients
Jun Wang, Thomas Kunzke, Verena M. Prade, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 13, pp. 2865-2877
Open Access | Times Cited: 47
High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer
Chaemin Lim, Duhyeong Hwang, Mostafa Yazdimamaghani, et al.
Nano Today (2023) Vol. 51, pp. 101884-101884
Open Access | Times Cited: 23
The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
Yu Ma, Ting Wang, Xudong Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 15
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 14
STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance
Tianye Li, Weijiang Zhang, Mengke Niu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis
Francisco Cézar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Barbara Lins Silva, et al.
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access | Times Cited: 1
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access | Times Cited: 1
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
María Merino, Teresa Lozano, Noëlia Casares, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 45
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Г. А. Жулай, Е. К. Олейник
Scandinavian Journal of Immunology (2021) Vol. 95, Iss. 3
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top